AUS
NZ
UK
CA
USA
IND
Imugene Limited (ASX:IMU), a clinical-stage cellular therapy firm, has reported a third patient response in the concurrent Bruton Tyrosine Kinase inhibitor (BTKi) cohort of its azer-cel Phase 1b clinical trial. The latest update highlights a second Follicular Lymphoma patient achieving a partial response despite prior progression on BTKi therapy. This milestone reinforces early clinical evidence in a patient group facing significant unmet medical needs, as the global BTKi market confronts resistance and disease progression challenges impacting thousands worldwide.
Key Points
- Imugene Limited (ASX:IMU) is advancing allogeneic CAR T therapies targeting blood cancers in clinical development.
- The azer-cel Phase 1b trial’s concurrent BTKi cohort has recorded its third patient response, with the latest being the second Follicular Lymphoma responder.
- The responding patient, previously progressing on BTKi therapy, showed a partial response at Day 28; five patients have been dosed in this cohort so far.
- Both Follicular Lymphoma patients treated concurrently with azer-cel and BTKi have responded, with ongoing enrolment at ten US and five Australian sites.
Azer-cel’s Off-the-Shelf Allogeneic CAR T Therapy Offers Operational Benefits
Azer-cel (azercabtagene zapreleucel) is an off-the-shelf, allogeneic CAR T cell therapy targeting CD19, a common antigen on B-cell malignancies. Unlike autologous CAR T treatments requiring 3-6 weeks for patient-specific manufacturing, azer-cel is derived from healthy donor T cells and can be administered within days. This off-the-shelf design provides significant logistical and operational advantages, enabling faster treatment initiation and wider patient accessibility.
Imugene’s allogeneic CAR T platform strategically positions the company to overcome manufacturing and accessibility challenges inherent in autologous therapies. Azer-cel’s standardized, scalable production could reduce costs and improve outcomes by enabling earlier treatment. This approach aligns with oncology trends recognizing allogeneic CAR T therapies as a means to broaden CAR T adoption across patient populations.
Third Clinical Response in BTKi-Resistant Cohort Validates Combination Therapy Approach
Imugene’s latest update reveals a Follicular Lymphoma patient achieved a partial response at Day 28 following concurrent azer-cel and BTKi treatment. This patient is the second Follicular Lymphoma responder in the BTKi cohort and had previously progressed on BTKi therapy, underscoring the potential of combining azer-cel with BTK inhibitors to overcome resistance.
Both Follicular Lymphoma patients treated in this cohort have responded to combined azer-cel and BTKi therapy. Given the challenging nature of BTKi-resistant disease, these responses highlight meaningful clinical activity. To date, five patients have been dosed in the concurrent BTKi cohort, emphasizing early but promising results.
Addressing Unmet Needs in Follicular Lymphoma Despite Initial Treatment Success
Follicular Lymphoma, the most common indolent B-cell lymphoma, often responds initially to treatment but relapses in many patients, creating a persistent unmet medical need. The BTKi-resistant subset faces even fewer options after standard therapies fail.
By enrolling Follicular Lymphoma patients who progressed on BTKi therapy, the azer-cel trial targets this difficult-to-treat population. The concurrent BTKi cohort aims to test whether combining azer-cel with BTKi therapy can overcome resistance and restore efficacy in these patients.
Global BTKi Market and Resistance Challenges Highlight Therapeutic Opportunity
The BTKi market is projected to reach about US$12.0 billion by 2025, reflecting widespread use across B-cell malignancies. Despite initial success, resistance to BTK inhibitors develops in many patients, limiting further treatment options.
This resistance creates a significant clinical gap, positioning combination therapies like concurrent azer-cel and BTKi dosing as promising strategies to address disease progression in resistant patients and expand available treatments.
Phase 1b Trial Expands Across US and Australia with Multi-Centre Design
The ongoing azer-cel Phase 1b trial is an open-label, multi-centre study in the US and Australia, enrolling CAR T-naïve and previously treated patients with various Non-Hodgkin lymphomas, including Follicular Lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, Waldenström macroglobulinemia, and mantle cell lymphoma. Recently, the trial added a dedicated concurrent BTKi cohort for patients with prior BTKi failure.
Patient recruitment continues at ten US and five Australian sites, supporting broad geographic and patient diversity. The protocol includes azer-cel administration with lymphodepletion and interleukin-2 (IL-2) support, with initial data showing meaningful clinical responses.
Early Safety Profile Indicates Manageable Tolerability
Initial findings suggest that azer-cel combined with lymphodepletion and IL-2 is generally well tolerated, with a manageable safety profile in trial participants. While detailed safety data were not disclosed, these early observations support continued clinical evaluation.
As data are preliminary from a limited Phase 1b population, ongoing safety monitoring and data maturation are essential to validate these findings as the trial progresses.
Clinical Response and Data Maturation in Early Trial Stages
The Follicular Lymphoma patient’s partial response at Day 28 aligns with standard lymphoma response criteria, demonstrating early clinical benefit. Both Follicular Lymphoma patients in the concurrent BTKi cohort have shown responses, indicating consistent outcomes in this difficult population.
Imugene plans to provide further updates as additional data accumulate and mature. Current results represent early-stage findings, with no specific timelines for future data releases or trial completion provided.
Imugene’s Strategic Focus on Allogeneic CAR T Therapy Development
Imugene Limited is focused on advancing allogeneic CAR T therapies, with azer-cel as its lead asset, diverging from the conventional autologous CAR T model. The company’s strategy aims to address manufacturing and accessibility limitations by delivering off-the-shelf CAR T products.
Supported by international cancer experts, Imugene seeks to establish allogeneic CAR T therapy as a foundational cancer treatment, requiring successful clinical validation, regulatory approvals, and commercial scale-up. The concurrent BTKi cohort results mark progress toward these goals, though significant milestones remain.
Ongoing Patient Recruitment and Future Trial Updates
Enrollment continues across the azer-cel Phase 1b trial at ten US and five Australian sites. The company has not disclosed specific enrollment targets, completion timelines, or data readout dates.
Imugene intends to provide ongoing updates as the dataset matures and additional patient data become available. Investors should expect periodic announcements regarding patient responses, safety outcomes, and trial progression as recruitment and follow-up advance across trial sites.
